NZ601943A - Antibodies against cxcr4 - Google Patents
Antibodies against cxcr4Info
- Publication number
- NZ601943A NZ601943A NZ601943A NZ60194311A NZ601943A NZ 601943 A NZ601943 A NZ 601943A NZ 601943 A NZ601943 A NZ 601943A NZ 60194311 A NZ60194311 A NZ 60194311A NZ 601943 A NZ601943 A NZ 601943A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cxcr4
- antibody
- ligand
- inhibiting
- induced
- Prior art date
Links
- 101100441540 Xenopus laevis cxcr4-a gene Proteins 0.000 title 1
- 101100441541 Xenopus laevis cxcr4-b gene Proteins 0.000 title 1
- 239000003446 ligand Substances 0.000 abstract 4
- 230000006907 apoptotic process Effects 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 108091008928 CXC chemokine receptors Proteins 0.000 abstract 1
- 102000054900 CXCR Receptors Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 abstract 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 abstract 1
- 230000003185 calcium uptake Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000005012 migration Effects 0.000 abstract 1
- 238000013508 migration Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30306010P | 2010-02-10 | 2010-02-10 | |
| GBGB1002238.2A GB201002238D0 (en) | 2010-02-10 | 2010-02-10 | Antibodies |
| PCT/GB2011/000175 WO2011098762A2 (en) | 2010-02-10 | 2011-02-10 | Antibodies against cxcr4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ601943A true NZ601943A (en) | 2014-11-28 |
Family
ID=42110504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ601943A NZ601943A (en) | 2010-02-10 | 2011-02-10 | Antibodies against cxcr4 |
Country Status (16)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| WO2012178137A1 (en) | 2011-06-24 | 2012-12-27 | Gillies Stephen D | Light chain immunoglobulin fusion proteins and methods of use thereof |
| WO2014033252A1 (en) * | 2012-08-31 | 2014-03-06 | arGEN-X BV | Method for producing antibody molecules having inter-species, intra-target cross-reactivity |
| AU2014383868A1 (en) * | 2014-02-19 | 2016-09-08 | MicroConstants China Inc, Disabled Disabled Disabled | Chemokine receptor antagonist and its combinational therapy |
| US10647766B2 (en) * | 2014-12-17 | 2020-05-12 | Cancer Research Technology Limited | Anti-CXCL12 antibody molecules and their uses |
| KR102644875B1 (ko) | 2015-07-23 | 2024-03-06 | 베링거잉겔하임인터내쇼날유한회사 | Il-23a 및 b-세포 활성화 인자(baff)를 표적화하는 화합물 및 이의 용도 |
| EP3408378B1 (en) | 2016-01-25 | 2022-01-12 | NantCell, Inc. | Nk cells with altered cxcl12/cxcr4 signaling |
| US10111235B2 (en) * | 2016-02-15 | 2018-10-23 | Spidercloud Wireless, Inc. | Methods for centralized channel selection across different cells in a radio access network |
| CN116903741A (zh) | 2016-06-20 | 2023-10-20 | 科马布有限公司 | 特异性结合于pd-l1的抗体或其抗原结合片段及其用途 |
| JP7447388B2 (ja) | 2018-07-13 | 2024-03-12 | ナンジン レジェンド バイオテック カンパニー，リミテッド | 感染性疾患の治療のための共受容体システム |
| EP4087657A1 (en) | 2020-01-08 | 2022-11-16 | Synthis Therapeutics, Inc. | Alk5 inhibitor conjugates and uses thereof |
| EP4347643A4 (en) * | 2021-05-27 | 2025-09-17 | Us Gov Veterans Affairs | HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO STREPTOLYSIN O AND METHODS OF USE |
| KR20250112287A (ko) | 2022-12-12 | 2025-07-23 | 니뽄 다바코 산교 가부시키가이샤 | 담배 시트, 담배 시트를 제조하는 방법, 담배 충전물, 및 흡연 물품 |
| CN117003876B (zh) * | 2023-08-31 | 2024-06-18 | 恺佧生物科技(上海)有限公司 | 一种Anti-CXCR4膜蛋白抗体及其制备方法和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2437213A1 (fr) | 1978-09-28 | 1980-04-25 | Cm Ind | Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation |
| US4736866A (en) | 1984-06-22 | 1988-04-12 | President And Fellows Of Harvard College | Transgenic non-human mammals |
| WO1990010457A1 (en) | 1989-03-14 | 1990-09-20 | New York University | Method of treating hiv infections using immunotoxins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
| DE69332948T2 (de) | 1992-03-05 | 2003-11-27 | Board Of Regents, The University Of Texas System | Verwendung von Immunokonjugate zur Diagnose und/oder Therapie der vaskularisierten Tumoren |
| US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| DE19801265C1 (de) | 1998-01-15 | 1999-08-12 | Deutsches Krebsforsch | Inhibierung von CD95-unabhängiger Apoptose bei AIDS |
| US6863887B1 (en) | 1998-03-30 | 2005-03-08 | Northwest Biotherapeutics, Inc. | Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis |
| US6610834B1 (en) | 1998-11-18 | 2003-08-26 | Peter I. Lobo | Human IgM antibodies to chemokine receptors |
| WO2000064946A2 (en) | 1999-04-28 | 2000-11-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| US7005503B2 (en) | 2002-02-08 | 2006-02-28 | Genetastix Corporation | Human monoclonal antibody against coreceptors for human immunodeficiency virus |
| WO2003066830A2 (en) | 2002-02-08 | 2003-08-14 | Genetastix Corporation | Human monoclonal antibodies against membrane proteins |
| DE10240064A1 (de) * | 2002-08-30 | 2004-03-11 | Universitätsklinikum Freiburg | CXCR4-Rezeptor-Antagonisten |
| US20050266009A1 (en) | 2003-06-30 | 2005-12-01 | Savient Pharmaceuticals, Inc. | Antibodies and uses thereof |
| US7776564B2 (en) * | 2004-04-30 | 2010-08-17 | Five Prime Therapeutics, Inc. | Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use |
| EP1871807B1 (en) | 2005-02-18 | 2012-11-28 | Dana-Farber Cancer Institute, Inc. | Antibodies against cxcr4 and methods of use thereof |
| RS55740B1 (sr) | 2006-10-02 | 2017-07-31 | Squibb & Sons Inc | Humana antitela koja se vezuju za cxcr4 i njihove upotrebe |
| FR2915102B1 (fr) | 2007-04-23 | 2014-05-16 | Pf Medicament | Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer |
| CA2724409A1 (en) | 2008-05-14 | 2009-11-19 | Eli Lilly And Company | Anti-cxcr4 antibodies |
-
2010
- 2010-02-10 GB GBGB1002238.2A patent/GB201002238D0/en not_active Ceased
-
2011
- 2011-02-10 MX MX2012009144A patent/MX2012009144A/es not_active Application Discontinuation
- 2011-02-10 SG SG2012056321A patent/SG182795A1/en unknown
- 2011-02-10 JP JP2012552459A patent/JP6045914B2/ja not_active Expired - Fee Related
- 2011-02-10 EA EA201290759A patent/EA201290759A1/ru unknown
- 2011-02-10 WO PCT/GB2011/000175 patent/WO2011098762A2/en not_active Ceased
- 2011-02-10 NZ NZ601943A patent/NZ601943A/en not_active IP Right Cessation
- 2011-02-10 CA CA2788400A patent/CA2788400A1/en not_active Abandoned
- 2011-02-10 KR KR1020127023204A patent/KR20120130767A/ko not_active Ceased
- 2011-02-10 BR BR112012020173A patent/BR112012020173A2/pt not_active IP Right Cessation
- 2011-02-10 EP EP11730035A patent/EP2534177A2/en not_active Withdrawn
- 2011-02-10 US US13/024,698 patent/US8748107B2/en not_active Expired - Fee Related
- 2011-02-10 AU AU2011214179A patent/AU2011214179B2/en not_active Ceased
- 2011-02-10 CN CN201180019263.1A patent/CN103003306B/zh not_active Expired - Fee Related
-
2012
- 2012-08-13 ZA ZA2012/06055A patent/ZA201206055B/en unknown
- 2012-09-03 CO CO12150358A patent/CO6630117A2/es unknown
-
2014
- 2014-05-16 US US14/279,728 patent/US9353185B2/en not_active Expired - Fee Related
-
2016
- 2016-05-11 US US15/152,414 patent/US20160244527A1/en not_active Abandoned
- 2016-07-29 JP JP2016149925A patent/JP2017012179A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011098762A3 (en) | 2012-01-19 |
| US20110311449A1 (en) | 2011-12-22 |
| JP2017012179A (ja) | 2017-01-19 |
| KR20120130767A (ko) | 2012-12-03 |
| EA201290759A1 (ru) | 2013-03-29 |
| US20160244527A1 (en) | 2016-08-25 |
| SG182795A1 (en) | 2012-08-30 |
| JP6045914B2 (ja) | 2016-12-14 |
| US8748107B2 (en) | 2014-06-10 |
| GB201002238D0 (en) | 2010-03-31 |
| JP2013519367A (ja) | 2013-05-30 |
| EP2534177A2 (en) | 2012-12-19 |
| WO2011098762A8 (en) | 2011-10-20 |
| WO2011098762A2 (en) | 2011-08-18 |
| CN103003306B (zh) | 2016-09-07 |
| MX2012009144A (es) | 2012-10-01 |
| AU2011214179A1 (en) | 2012-09-13 |
| CO6630117A2 (es) | 2013-03-01 |
| US9353185B2 (en) | 2016-05-31 |
| BR112012020173A2 (pt) | 2019-09-24 |
| CA2788400A1 (en) | 2011-08-18 |
| ZA201206055B (en) | 2014-01-29 |
| CN103003306A (zh) | 2013-03-27 |
| US20140369925A1 (en) | 2014-12-18 |
| AU2011214179B2 (en) | 2015-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ601943A (en) | Antibodies against cxcr4 | |
| PH12012502215A1 (en) | Anti-fgfr2 antibodies | |
| MX2015004105A (es) | Anticuerpos monoclonales humanos anti-pd-l1 y metodos de uso. | |
| MY199247A (en) | ANTI-SIRPa ANTIBODIES | |
| JOP20210044A1 (ar) | الأجسام المضادة لـ cd38 | |
| UA106194C2 (ru) | Диагностика и лечение рака с применением антитела к ereg | |
| MX2019009654A (es) | Anticuerpos e inmunoconjugados del receptor 1 de folato y usos de los mismos. | |
| PH12019502302A1 (en) | Anti-pd-l1 antibody and use thereof | |
| MX341076B (es) | Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados. | |
| WO2007133822A8 (en) | Gitr antibodies for the treatment of cancer | |
| MX2017004311A (es) | Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos. | |
| MY176475A (en) | Human antibodies to pd-1 | |
| PH12015502112A1 (en) | Cancer treatment using antibodies that bind cell surface grp78 | |
| MX360671B (es) | Composición farmacéutica para el tratamiento y/o prevención del cáncer. | |
| NZ604510A (en) | Dilutable biocidal compositions and methods of use | |
| PH12013502201A1 (en) | Anti-b7-h3 antibody | |
| WO2013013025A3 (en) | Anti-cxcr4 antibodies and methods of use | |
| WO2010100056A3 (en) | Antibodies against a proliferating inducing ligand (april) | |
| NZ612175A (en) | Anti ccr4 antibodies and uses thereof | |
| IL188594A0 (en) | Anti-ccr7 receptor antibodies for the treatment of cancer | |
| WO2012006341A8 (en) | Anti-ron antibodies | |
| TN2012000466A1 (en) | Humanized anti cxcr4 antibodies for the treatment of cancer | |
| EA201071068A1 (ru) | Антитела к tyrp1 | |
| MX2009003039A (es) | Utilizacion de un anticuerpo anti-cd151 para el tratamiento del cancer. | |
| NZ602515A (en) | Proteins that bind pi16 and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 10 FEB 2018 BY PHILLIPS ORMONDE FITZPATRICK Effective date: 20150605 |
|
| LAPS | Patent lapsed |